After allogeneic hematopoietic cell transplantation (HCT), approximately 8% of patients develop a syndrome of cutaneous sclerosis which can severely affect their mobility and quality of life, and is often refractory to standard immune suppressive therapies. Recent clinical and translational data suggest that alloimmune B cells and in particular, agonistic antibodies against platelet derived growth factor receptor (PDGFR), may be responsible for cutaneous collagen deposition. We hypothesize that targeting this pathogenic mechanism using either rituximab (a FDA-approved humanized anti-CD20 antibody) to eliminate alloimmune B cells or imatinib (a FDA-approved tyrosine kinase inhibitor) to block PDGFR activity will effectively treat cutaneous sclerosis. To test this hypothesis, we propose a 70 patient two-arm phase II crossover trial of imatinib and rituximab to determine efficacy against HCT-associated cutaneous sclerosis. Correlative studies of skin biopsies and blood samples will confirm target specificity. Blood measurements include: 1) B cell subsets, 2) B cell stimulatory factors and 3) allo- and auto-antibody changes. Skin assays include: 1) phosphorylation status of PDGFR, ABL, and other tyrosine kinase receptors, 2) B cell infiltration, antibody deposition, and complement activation, 3) collagen deposition, and 4) gene expression studies. Ancillary studies will evaluate clinical assessment tools and patient-reported measures. This project will provide insights into the pathogenesis of and best treatment for HCT-associated cutaneous sclerosis.

Public Health Relevance

Cutaneous sclerosis (skin thickening causing decreased flexibility) poses a vexing clinical problem with high morbidity due to ineffective therapies. By treating 70 people with HCT-associated cutaneous sclerosis with either rituximab or imatinib and testing skin and blood samples, we hope to learn how to prevent the disease or develop better treatments. Knowledge gained from these studies may help us to treat other patients with sclerosis

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-HOP-Y)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Inamoto, Yoshihiro; Martin, Paul J; Storer, Barry E et al. (2014) Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. Haematologica 99:1618-23
Inamoto, Yoshihiro; Flowers, Mary E D; Sandmaier, Brenda M et al. (2014) Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. Blood 124:1363-71
El-Jawahri, Areej; Pidala, Joseph; Inamoto, Yoshi et al. (2014) Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant 20:1341-8
Inamoto, Yoshihiro; Pidala, Joseph; Chai, Xiaoyu et al. (2014) Assessment of joint and fascia manifestations in chronic graft-versus-host disease. Arthritis Rheumatol 66:1044-52
Palmer, Jeanne; Williams, Kirsten; Inamoto, Yoshihiro et al. (2014) Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease. Biol Blood Marrow Transplant 20:337-44
Kitko, Carrie L; Levine, John E; Storer, Barry E et al. (2014) Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. Blood 123:786-93
Inamoto, Yoshihiro; Kim, Dennis D; Storer, Barry E et al. (2014) Application of CIBMTR risk score to NIH chronic GVHD at individual centers. Blood 123:453-5
Allen, Jessica L; Tata, Prasanthi V; Fore, Matthew S et al. (2014) Increased BCR responsiveness in B cells from patients with chronic GVHD. Blood 123:2108-15
Duarte, R F; Greinix, H; Rabin, B et al. (2014) Uptake and use of recommendations for the diagnosis, severity scoring and management of chronic GVHD: an international survey of the EBMT-NCI Chronic GVHD Task Force. Bone Marrow Transplant 49:49-54
Inamoto, Y; Jagasia, M; Wood, W A et al. (2014) Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD. Bone Marrow Transplant 49:532-8

Showing the most recent 10 out of 11 publications